ChemoCentryx CEO Thomas Schall's 2021 pay rises 7% to $9M
ChemoCentryx reports 2021 executive compensation
By ExecPay News
Published: April 5, 2022
ChemoCentryx reported fiscal year 2021 executive compensation information on April 5, 2022.
In 2021, five executives at ChemoCentryx received on average a compensation package of $4.5M, a 1% decrease compared to previous year.
Average pay of disclosed executives at ChemoCentryx
Thomas J. Schall, Chief Executive Officer, received $9M in total, which increased by 7% compared to 2020. 58% of Schall's compensation, or $5.2M, was in stock awards. Schall also received $465K in non-equity incentive plan, $2.6M in option awards, $737K in salary, as well as $3.6K in other compensation.
Tausif Butt, Chief Operating Officer, received a compensation package of $5.9M. 83% of the compensation package, or $4.9M, was in option awards.
Susan M. Kanaya, Secretary, earned $3.9M in 2021, a 35% increase compared to previous year.
Markus J. Cappel, Chief Business Officer, received $2.6M in 2021, which increases by 15% compared to 2020.
Rita I. Jain, Chief Medical Officer, earned $1M in 2021.
Related executives
You may also like
Source: SEC filing on April 5, 2022.